MED12 exon 2 mutations are common in uterine leiomyomas from South African patients

Netta Mäkinen; Hanna-Riikka Heinonen; Shane Moore; Ian Tomlinson; Zephne van der Spuy; Lauri Aaltonen

doi:10.18632/oncotarget.370

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Brief Reports:

MED12 exon 2 mutations are common in uterine leiomyomas from South African patients

Netta Mäkinen, Hanna-Riikka Heinonen, Shane Moore, Ian Tomlinson, Zephne van der Spuy and Lauri Aaltonen _

PDF | HTML | How to cite

Oncotarget. 2011; 2:966-969. https://doi.org/10.18632/oncotarget.370

Metrics: PDF 3287 views | HTML 4120 views | ?

Abstract

Netta Mäkinen¹, Hanna-Riikka Heinonen¹, Shane Moore², Ian P.M. Tomlinson³, Zephne M. van der Spuy², and Lauri A. Aaltonen¹

¹ Department of Medical Genetics, Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland

² Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town, South Africa

³ Wellcome Trust Centre for Human Genetics and NIHR Comprehensive Biomedical Research Centre, Nuffield Department of Clinical Medicine, Roosevelt Drive, University of Oxford, Oxford OX3 7BN, UK

Received: November 30, 2011; Accepted: December 9, 2011; Published: December 19, 2011;

Keywords:Uterine leiomyoma, fibroid, MED12, ethnicity

Correspondence:

Lauri A. Aaltonen, email:

Abstract

Uterine leiomyomas, or fibroids, are extremely common tumors. Regardless of their benign nature, fibroids can cause considerable morbidity. Women with African ancestry have a threefold increased risk of developing uterine leiomyomas with a greater symptom severity when compared to white women. Recently, we demonstrated that exon 2 of the MED12 gene is somatically altered in up to 70 per cent of uterine leiomyomas in a series of Finnish (Caucasian) patients. To validate these results in other populations, we sequenced a set of 28 uterine leiomyomas for MED12 exon 2 mutations from 18 different Black African or Coloured South African patients. We observed 14 mutation positive lesions (50%). When corrected by tumor size, these results are very similar to those derived in the Finnish material. This study confirms a major role of MED12 in the genesis of leiomyomas, regardless of ethnicity.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 370

Publication Alerts

Post-Publication Promotion

Publication Discount

Brief Reports:

MED12 exon 2 mutations are common in uterine leiomyomas from South African patients

Abstract